399 — Innovative Pharmaceutical Biotech Balance Sheet
0.000.00%
Last trade - 00:00
- HK$344.64m
- HK$2.27bn
- HK$8.08m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 17.1 | 22.9 | 8.99 | 4.08 | 1.33 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 21.2 | 15.6 | 15.3 | 9.5 | 6.41 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 44.5 | 42.2 | 28.8 | 18.9 | 9.88 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.095 | 3.47 | 1.19 | 2.82 | 0.941 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Total Assets | 1,579 | 1,419 | 1,403 | 1,395 | 1,384 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 32.4 | 70.5 | 801 | 99.8 | 1,147 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,654 | 1,809 | 1,999 | 1,944 | 2,179 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | -75 | -390 | -595 | -549 | -795 |
Total Liabilities & Shareholders' Equity | 1,579 | 1,419 | 1,403 | 1,395 | 1,384 |
Total Common Shares Outstanding |